OPTASXOpthea Ltd

OPT price activity

Last Price

Change (24hr)

AUD (%)

Volume

Volume (4w avg)

Previous Close

N/A

Last Trade

OPT price performance

-98%

YTD

-98%

OPT price fundamentals

N/A

Shares Issued

N/A

Earnings Per Share (EPS)

N/A

Dividends Per Share (DPS)

N/A

P/E Ratio

Price market cap

Market cap

N/A

AU-ASX rank

N/A

Sector Rank

N/A

OPT details

View company profile

View company website

View AU-ASX Official Page

OPT Market Signals

More ways to discover

Browse Australia news Discover ASX signals Browse all ASX stocks

Opthea Ltd (AU-ASX: OPT)

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Price: A$0.01

Sector: Healthcare — Biotechnology